Page 61 - Aintained News Today

In a research note, Barclays analyst Fernando Gil De Santivanes has maintained his recommendation on the stock with a Neutral rating. The target price is slightly modified from 6.60 to 6.50 EUR. | February 8, 2022

Initially Neutral on the company, RBCs analyst Anke Reingen maintained his recommendation. The target price is reduced from EUR 15.00 to EUR 14.50. | February 3, 2022

In a research note, RBC analyst Alexander Wheeler has maintained his recommendation on the stock with a Buy rating. The target price is unchanged at EUR 9.25. | February 4, 2022

In a research note, Barclays analyst Claudia Gaspari has maintained his recommendation on the stock with a Buy rating. Previously set at CHF 445, the target price has been slightly modified to CHF... | February 2, 2022

In a research note, UBS analyst Timothy Arcuri has maintained his recommendation on the stock with a Neutral rating. The target price is lowered from USD 58 to USD 53. | January 27, 2022

Initially Neutral on the company, RBCs analyst Anke Reingen maintained his recommendation. The target price is reviewed upwards from EUR 13 to EUR 14. | January 27, 2022

In a research note, JP Morgan analyst Jose Asumendi has maintained his recommendation on the stock with a Buy rating. The target price is unchanged at EUR 62. | January 27, 2022

In a research note, Jefferies analyst Alexander Thiel has maintained his recommendation on the stock with a Buy rating. The target price remains unchanged at EUR 201. | January 26, 2022

In a research note, Goldman Sachs analyst Rob Joyce has maintained his recommendation on the stock with a Neutral rating. The target price is set at 30.50 versus 31.00 EUR. | January 24, 2022

SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY), Monday announced that The Lancet has published two papers highlighting one-year results from four pivotal Phase III